Logos Global Management LP
- SEC CIK
- 0001792126
- Latest filing
- Aug 14, 2026
Holdings in Q2 2024
Holdings as of Jun 30, 2024, filed Aug 27, 2024. Long positions only; changes compare share counts with Q1 2024.
- Positions
- 51
- +1 vs. Q1 2024
- Portfolio value
- $867.8M
- −$82.4M (−8.7%) vs. Q1 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| IDYAIDEAYA Biosciences, Inc. | COM | 1,700,000 | $59.7M | 6.9% | +200,000+13.3% | Added | History |
| ARGXArgenx SE | SPONSORED ADR | 135,000 | $58.1M | 6.7% | +135,000 | New | History |
| MRUSMerus N.V. | COM | 850,000 | $50.3M | 5.8% | +850,000 | New | History |
| RVMDRevolution Medicines, Inc. | COM | 1,200,000 | $46.6M | 5.4% | +1,200,000 | New | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 1,100,000 | $43.2M | 5.0% | +379,942+52.8% | Added | History |
| IRONDisc Medicine, Inc. | COM | 925,000 | $41.7M | 4.8% | +925,000 | New | History |
| OCULOcular Therapeutix, Inc | COM | 5,150,000 | $35.2M | 4.1% | −661,436−11.4% | Reduced | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 3,208,875 | $34.7M | 4.0% | −1,175,000−26.8% | Reduced | History |
| VERAVera Therapeutics, Inc. | CL A | 950,000 | $34.4M | 4.0% | +375,000+65.2% | Added | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 750,000 | $33.0M | 3.8% | +750,000 | New | History |
| JANXJanux Therapeutics, Inc. | COM | 750,000 | $31.4M | 3.6% | +600,000+400.0% | Added | History |
| XNCRXencor Inc | COM | 1,500,000 | $28.4M | 3.3% | +850,000+130.8% | Added | History |
| SLNSilence Therapeutics plc | ADS | 1,476,061 | $28.0M | 3.2% | 00.0% | Unchanged | History |
| SRPTSarepta Therapeutics, Inc. | COM | 150,000 | $23.7M | 2.7% | −250,000−62.5% | Reduced | History |
| AKROAkero Therapeutics, Inc. | COM | 800,000 | $18.8M | 2.2% | 00.0% | Unchanged | History |
| DSGNDesign Therapeutics, Inc. | COM | 5,032,501 | $16.9M | 1.9% | 00.0% | Unchanged | History |
| ANNXAnnexon, Inc. | COM | 3,300,000 | $16.2M | 1.9% | +250,000+8.2% | Added | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 400,000 | $15.3M | 1.8% | −400,000−50.0% | Reduced | History |
| IMVTImmunovant, Inc. | COM | 575,000 | $15.2M | 1.7% | −1,200,000−67.6% | Reduced | History |
| NUVLNuvalent, Inc. | COM | 195,000 | $14.8M | 1.7% | +195,000 | New | History |
| XENEXenon Pharmaceuticals Inc. | COM | 375,000 | $14.6M | 1.7% | +375,000 | New | History |
| IONSIonis Pharmaceuticals Inc | COM | 300,000 | $14.3M | 1.6% | +300,000 | New | History |
| STOKStoke Therapeutics, Inc. | COM | 1,050,000 | $14.2M | 1.6% | +1,050,000 | New | History |
| ERASErasca, Inc. | COM | 5,900,000 | $13.9M | 1.6% | +5,900,000 | New | History |
| ELVNEnliven Therapeutics, Inc. | COM | 595,000 | $13.9M | 1.6% | −979,220−62.2% | Reduced | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 575,000 | $13.5M | 1.6% | +325,000+130.0% | Added | History |
| ENGNenGene Therapeutics Inc. | COM | 1,200,000 | $11.3M | 1.3% | +400,000+50.0% | Added | History |
| Cybin Ord23256X100 | COM | 40,000,000 | $10.8M | 1.2% | 00.0% | Unchanged | – |
| SKYESkye Bioscience, Inc. | COM NEW | 1,301,518 | $10.4M | 1.2% | +1,301,518 | New | History |
| ELEVElevation Acquisition Group Inc. | COM | 3,850,000 | $10.4M | 1.2% | +2,850,000+285.0% | Added | History |
| DYNDyne Therapeutics, Inc. | COM | 265,000 | $9.35M | 1.1% | −1,465,000−84.7% | Reduced | History |
| BHVNBiohaven Ltd. | COM | 250,000 | $8.68M | 1.0% | +250,000 | New | History |
| RLAYRelay Therapeutics, Inc. | COM | 1,300,000 | $8.48M | 1.0% | +1,300,000 | New | History |
| TRVITrevi Therapeutics, Inc. | COM | 2,800,000 | $8.34M | 1.0% | +600,000+27.3% | Added | History |
| RCKTRocket Pharmaceuticals, Inc. | COM | 350,000 | $7.54M | 0.9% | −950,000−73.1% | Reduced | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 1,159,030 | $7.00M | 0.8% | +901,050+349.3% | Added | History |
| AVTXAvalo Therapeutics, Inc. | COM NEW | 539,079 | $6.72M | 0.8% | +539,079 | New | History |
| LCTXLineage Cell Therapeutics, Inc. | COM | 4,700,000 | $4.69M | 0.5% | −1,550,000−24.8% | Reduced | History |
| ATYRaTYR PHARMA INC | COM NEW | 3,000,000 | $4.68M | 0.5% | −100,000−3.2% | Reduced | History |
| ATXSAstria Therapeutics, Inc. | COM | 500,000 | $4.55M | 0.5% | −744,960−59.8% | Reduced | History |
| RAPPRapport Therapeutics, Inc. | COM | 208,910 | $4.37M | 0.5% | +208,910 | New | History |
| NXTCNextCure, Inc. | COM | 2,500,000 | $3.98M | 0.5% | +575,000+29.9% | Added | History |
| NMRANeumora Therapeutics, Inc. | COM | 300,000 | $2.95M | 0.3% | −82,345−21.5% | Reduced | History |
| ALLKAllakos Inc. | COM | 2,900,000 | $2.90M | 0.3% | 00.0% | Unchanged | History |
| ADVMAdverum Biotechnologies, Inc. | COM NEW | 416,666 | $2.86M | 0.3% | −1,083,333−72.2% | Reduced | History |
| APLTApplied Therapeutics, Inc. | COM | 600,000 | $2.66M | 0.3% | −750,000−55.6% | Reduced | History |
| RNACCartesian Therapeutics, Inc. | COM NEW | 90,000 | $2.43M | 0.3% | +90,000 | New | History |
| UNCYUnicycive Therapeutics, Inc. | COM | 3,469,927 | $1.74M | 0.2% | 00.0% | Unchanged | History |
| IOBTIO Biotech, Inc. | COM | 493,827 | $577.8K | 0.1% | 00.0% | Unchanged | History |
| BOLDBoundless Bio, Inc. | COM | 117,806 | $433.1K | <0.1% | −82,194−41.1% | Reduced | History |
| Nuvation Bio Inc.67080N119 | *W EXP 07/07/202 | 66,666 | $10.7K | <0.1% | 00.0% | Unchanged | – |
Options (6)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| State Street SPDR S&P Biotech ETF78464A870 | ETF | $185.4M | – |
| SRPTSarepta Therapeutics, Inc. | COM | – | $79.0M |
| APLSApellis Pharmaceuticals, Inc. | COM | – | $76.7M |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | – | $17.7M |
| FULCFulcrum Therapeutics, Inc. | COM | – | $9.30M |
| ANNXAnnexon, Inc. | COM | – | $7.35M |
Sold out since Q1 2024 (15)
Positions held at the end of Q1 2024 that are gone from this filing.
| Security | Class | Shares in Q1 2024 | Value in Q1 2024 | % of portfolio in Q1 2024 | History |
|---|---|---|---|---|---|
| IMCRImmunocore Holdings plc | ADS | 900,000 | $58.5M | 6.2% | History |
| GERNGeron Corp | COM | 9,000,000 | $29.7M | 3.1% | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 650,000 | $27.3M | 2.9% | History |
| CGONCG Oncology, Inc. | COM | 300,000 | $13.2M | 1.4% | History |
| KYTXKyverna Therapeutics, Inc. | COM | 500,000 | $12.4M | 1.3% | History |
| VRDNViridian Therapeutics, Inc. | COM | 700,000 | $12.3M | 1.3% | History |
| CGEMCullinan Therapeutics, Inc. | COM | 700,000 | $11.9M | 1.3% | History |
| IMTXImmatics N.V. | SHS | 1,000,000 | $10.5M | 1.1% | History |
| PRAXPraxis Precision Medicines, Inc. | COM NEW | 150,000 | $9.15M | 1.0% | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 350,000 | $8.33M | 0.9% | History |
| CYTKCytokinetics Inc | COM NEW | 100,000 | $7.01M | 0.7% | History |
| KURAKura Oncology, Inc. | COM | 300,000 | $6.40M | 0.7% | History |
| TRMLTourmaline Bio, Inc. | COM | 99,208 | $2.27M | 0.2% | History |
| IMUXImmunic, Inc. | COM | 421,184 | $556.0K | 0.1% | History |
| CYPHCypherpunk Technologies Inc. | COM NEW | 39,500 | $105.1K | <0.1% | History |